The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with type 2 diabetes, ...

STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Now they are being found to treat cardiovascular and kidney disease, and are being tested for Alzheimer ... Already one in ...

GLP-1 drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

In a press release, Novo Nordisk said the regimen “appeared to have a safe and well-tolerated profile in line with previous ...